Get the Stockscreener App
4.64
0.64%
-0.03
After Hours:
4.87
0.23
+4.96%
4 D Molecular Therapeutics Inc Stock (FDMT) Latest News
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
4D Molecular Therapeutics’ (FDMT) Sell (D-) Rating Reiterated at Weiss Ratings - Defense World
4DMT to Participate in Upcoming Investor Conferences - GlobeNewswire
4D Molecular's March Investor Showcase: What These Two Major Conference Appearances Signal - StockTitan
4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression - Seeking Alpha
4D Molecular Therapeutics' SWOT analysis: gene therapy firm's stock faces durability test - Investing.com
4D Molecular Therapeutics (NASDAQ:FDMT) Given New $30.00 Price Target at Chardan Capital - MarketBeat
Peapod Lane Capital LLC Purchases New Shares in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - MarketBeat
Jefferies cuts 4D Molecular Therapeutics target to $40 - MSN
FDMT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 4D Molecular Therapeutics, Inc. and Encourages Stockholders to Contact the Firm! - ACCESS Newswire
FDMT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 4D Molecular Therapeutics, Inc. and Encourages Investors to Contact the Firm! - ACCESS Newswire
FDMT stock touches 52-week low at $4.42 amid sharp annual decline - Investing.com India
4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Lowered to $30.00 at Chardan Capital - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given "Buy" Rating at HC Wainwright - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc.FDMT - PR Newswire
Gene Therapy In CNS Disorder Treatment Market Size Report 2032 | - openPR
Chardan Lowers Price Target on 4D Molecular Therapeutics to $30 From $39, Keeps Buy Rating - Marketscreener.com
4D Molecular Therapeutics’ (FDMT) Buy Rating Reaffirmed at HC Wainwright - Defense World
BMO Capital Markets Downgrades 4D Molecular Therapeutics Inc (FDMT) to a Market perform from an Outperform - Knox Daily
Jefferies cuts 4D Molecular Therapeutics target to $40 By Investing.com - Investing.com South Africa
4D’s new data in wet AMD bolster its phase III study vision - BioWorld Online
H.C. Wainwright maintains buy on 4D Molecular Therapeutics stock - MSN
4D Molecular Therapeutics (NASDAQ:FDMT) Earns “Buy” Rating from HC Wainwright - Armenian Reporter
Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study - Benzinga
Healthy Upside Potential: 4D Molecular Therapeutics Inc (FDMT) - SETE News
H.C. Wainwright maintains buy on 4D Molecular Therapeutics stock By Investing.com - Investing.com South Africa
Barrick Gold Corp (GOLD) receives a Neutral rating from BofA Securities - Knox Daily
A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 9 Analysts - Benzinga
ForexTV | Small Business Resources - ForexTV.com
4D Molecular Therapeutics Reports Positive Interim Data From Phase 2b Trial For Wet AMD - Nasdaq
4DMT Presents Positive 52-Week Results from Phase 2b Cohort - GlobeNewswire
There Is A Lot Of Upside Potential For 4D Molecular Therapeutics Inc(NASDAQ: FDMT) - Stocks Register
How Alibaba Stock Could Defy Trade Tariffs and Surge Higher - The Globe and Mail
Weiss Ratings Reiterates Sell (D-) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - MarketBeat
A better buy-in window may exist right now for 4D Molecular Therapeutics Inc (FDMT) - SETE News
Scrip Asks... What Does 2025 Hold For Biopharma? Part 5: Clinical Trials Trends - Citeline News & Insights
Market Insights: 4D Molecular Therapeutics Inc (FDMT)’s Notable Drop of -0.17, Closing at 5.92 - The Dwinnex
4D Molecular Therapeutics Inc (FDMT) deserves deeper analysis - US Post News
4D Molecular Therapeutics Inc [FDMT] Chief Legal Officer makes an insider sale of 500 shares worth $8165.0. - Knox Daily
X-Linked Retinitis Pigmentosa Clinical Trials 2025: EMA, PDMA, - openPR
BJ’s Wholesale Club Holdings Inc (BJ) may enjoy gains as insiders got busy in the recent days - Knox Daily
Monitoring Allstate Corp (ALL) after recent insider movements - Knox Daily
The Potential Rise in the Price of Cardlytics Inc (CDLX) following insiders activity - Knox Daily
The Attractiveness of Investing In Bloomin Brands Inc (BLMN) is Growing - Knox Daily
Charting the Course: 4D Molecular Therapeutics Inc’s FDMT Stock Prospects - The InvestChronicle
Weiss Ratings Reaffirms Sell (D-) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
4DMT Announces Corporate Webcast to Review Interim 52-week - GlobeNewswire
4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population - Marketscreener.com
Breakthrough Eye Treatment Data: 4D Molecular's AMD Trial Results Coming February - StockTitan
Analysts Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) PT at $38.56 - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc.FDMT - Longview News-Journal
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
FDMT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 4D Molecular Therapeutics, Inc. and Encourages Shareholders to Contact the Firm! - ACCESS Newswire
Top US Penny Stocks To Watch In January 2025 - Simply Wall St
Cantor Fitzgerald Estimates FDMT FY2025 Earnings - MarketBeat
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Assenagon Asset Management S.A. Sells 889,884 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
FDMT stock touches 52-week low at $4.48 amid market challenges - MSN
4D Molecular Therapeutics' (FDMT) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):